<SEC-DOCUMENT>0001854270-23-000012.txt : 20230127
<SEC-HEADER>0001854270-23-000012.hdr.sgml : 20230127
<ACCEPTANCE-DATETIME>20230127073653
ACCESSION NUMBER:		0001854270-23-000012
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230127
DATE AS OF CHANGE:		20230127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Senti Biosciences, Inc.
		CENTRAL INDEX KEY:			0001854270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				862437900
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267390
		FILM NUMBER:		23559678

	BUSINESS ADDRESS:	
		STREET 1:		2 CORPORATE DRIVE, FIRST FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 382-3281

	MAIL ADDRESS:	
		STREET 1:		2 CORPORATE DRIVE, FIRST FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Senti Biosciences, Inc.\
		DATE OF NAME CHANGE:	20220615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dynamics Special Purpose Corp.
		DATE OF NAME CHANGE:	20210331
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a20230127prospectussupplem.htm
<DESCRIPTION>424B3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4b0fa184400145f79db7b9ae98b39163_69"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Filed Pursuant to Rule 424(b)(3)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">                                                                                                                      </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Registration No. 333-267390</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Prospectus Supplement No. 3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(To Prospectus dated September 29, 2022)</font></div><div><font><br></font></div><div style="text-align:center"><img alt="senti_logoxfilings.jpg" src="senti_logoxfilings.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:218px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:112%">SENTI BIOSCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:112%">Up to 8,727,049 Shares of Common Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">__________________</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This prospectus supplement no. 3 (this &#8220;Prospectus Supplement&#8221;) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the &#8220;Prospectus&#8221;) which forms part of our Registration Statement on Form S-1 (Registration Statement No. 333-267390). This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January&#160;27, 2023 (the &#8220;Form 8-K&#8221;). Accordingly, we have attached the Form 8-K to this Prospectus Supplement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our common stock is listed on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;SNTI&#8221;. On January&#160;26, 2023, the last quoted sale price for the Senti Common Shares as reported on Nasdaq was $1.83 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">We are an &#8220;emerging growth company&#8221; under applicable federal securities laws and will be subject to reduced public company reporting requirements.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">__________________</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in &#8220;Risk Factors&#8221; beginning on page 8 of the Prospectus.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The date of this Prospectus Supplement is January&#160;27, 2023.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4b0fa184400145f79db7b9ae98b39163_1"></div><hr style="page-break-after:always"><div style="min-height:31.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">FORM 8-K</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CURRENT REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Pursuant to Section 13 or 15(d)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">of the Securities Exchange Act of 1934</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Date of Report (Date of earliest event reported)&#58; January 27, 2023</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:31.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">001-40440</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">86-2437900</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">of incorporation)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Commission</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">File Number)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(IRS Employer</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identification No.)</font></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2 Corporate Drive, First Floor</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">South San Francisco, California 94080</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices including zip code)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registrant&#8217;s telephone number, including area code&#58; (650) 382-3281</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Former name or former address, if changed since last report)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:2.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:43.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">on which registered</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Common Stock, par value $0.0001 per share</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">SNTI</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">The Nasdaq Global Market</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company &#9746;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9746;</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div></div></div><div id="i4b0fa184400145f79db7b9ae98b39163_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7.01.&#160;&#160;&#160;&#160;Regulation FD Disclosure.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reference is made to the disclosure set forth below in Item 8.01 of this Current Report on Form 8-K which is incorporated herein by reference.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 27, 2023, Senti Biosciences, Inc., (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) issued a press release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) titled, &#8220;Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies&#59; Updates Cash Runway Guidance,&#8221; a copy of which is furnished herewith as Exhibit 99.1. The information in this Item 7.01 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Securities Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), as amended or the Exchange Act. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01.&#160;&#160;&#160;&#160;Other Events.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 27, 2023, the Company announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to develop Gene Circuits for other programs. The Company also announced that it does not intend to devote its own resources to the development of SENTI-301A for the treatment of hepatocellular carcinoma at this time, and is actively pursuing strategic geographic partnerships for further clinical development of SENTI-301A. This business realignment will streamline internal efforts and is expected to extend the Company&#8217;s cash runway through at least the first quarter of 2024. In connection with this announcement, the Company has also updated certain corporate information in a  presentation slide deck. A copy of this corporate presentation is filed herewith as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cautionary Statement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This filing and the exhibits include &#8220;forward-looking statements&#8221; within the meaning of  Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Important factors that may cause actual results to differ materially from those described in the forward-looking statements are disclosed in the respective exhibits and in the &#8220;Risk Factors&#8221; contained in the Company&#8217;s Form 10-Q filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on November 10, 2022, and other filings we make with the Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.</font></div><div><font><br></font></div><div id="i4b0fa184400145f79db7b9ae98b39163_10"></div><div style="-sec-extract:summary"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01 Financial Statements and Exhibits.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000185427023000008/a20230127ex991pressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press Release, dated as of January 27, 2023</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1854270/000185427023000008/corporatepresentation_1-.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Corporate presentation</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4b0fa184400145f79db7b9ae98b39163_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">SENTI BIOSCIENCES, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">January 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Timothy Lu</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Timothy Lu, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer &#38; President</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>senti_logoxfilings.jpg
<TEXT>
begin 644 senti_logoxfilings.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Z -H# 2(  A$! Q$!_\0
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M'H17W924AW(MI#9 S[U\V?"7X5^*?#?[4/COQ3J&EO;Z%J$++;76\'S"6&,
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
